Obesity Medicine最新文献

{"title":"“Efficacy and safety of liraglutide in pediatric Obesity:A systematic review and meta analysis of randomized controlled trials”","authors":"Abdullah Afridi ,&nbsp;Fathimathul Henna ,&nbsp;Umaima Cheema ,&nbsp;Ayesha Sehar ,&nbsp;Muhammad Fakhir Iftikhar Rana ,&nbsp;Areej Dar ,&nbsp;Bibi Hafza ,&nbsp;Iqra khan ,&nbsp;Laiba Ali Khan ,&nbsp;Aafeen Mujeeb ,&nbsp;Ayesha Khalid Sheikhani ,&nbsp;Insha Habib ,&nbsp;Muhammad Abdullah Ali ,&nbsp;Momina Ali ,&nbsp;Mizhgan Abid ,&nbsp;Ansar Hussain","doi":"10.1016/j.obmed.2025.100605","DOIUrl":"10.1016/j.obmed.2025.100605","url":null,"abstract":"<div><h3>Introduction</h3><div>Liraglutide, a GLP-1 receptor agonist, has been explored for its potential benefits in managing paediatric obesity. This meta-analysis aims to assess the efficacy and safety of liraglutide compared to placebo in this paediatric population with obesity.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) on liraglutide in children with obesity. Five studies with 247 participants were included. Primary outcomes included changes in BMI SDS, BMI, and body weight, and secondary outcomes included fasting serum insulin, HbA1c, fasting plasma glucose, SBP, DSP, and safety outcomes.</div></div><div><h3>Results</h3><div>The meta-analysis included five randomized controlled trials with 247 participants evaluating liraglutide in pediatric obesity. Liraglutide significantly reduced BMI SDS, with a pooled mean difference of −0.17 (p = 0.003), BMI (mean difference: 1.28, p = 0.0008), and body weight (mean difference: 1.83, p = 0.03). Secondary outcomes showed significant reductions in fasting serum insulin levels (pooled effect size: 0.39, p &lt; 0.00001), but no significant effects were observed for DSP (p = 0.29), fasting plasma glucose (p = 0.07), HbA1c (p = 0.09), or systolic blood pressure (p = 0.09). Safety analysis revealed a higher incidence of adverse events in the treatment group (risk ratio: 1.25, p = 0.18), but no significant differences were found in serious adverse events or adverse events leading to therapy discontinuation.</div></div><div><h3>Conclusions</h3><div>Liraglutide is effective in reducing BMI SDS, BMI, and body weight in pediatric obesity. While it significantly reduces fasting serum insulin levels, other secondary outcomes did not show significant changes. The safety profile of liraglutide shows a higher incidence of adverse events but no increase in serious adverse events or discontinuation rates. These findings support liraglutide's role as an effective and manageable treatment option for pediatric obesity.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100605"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143800235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mechanisms of obesity and its effect on female infertility","authors":"Mahla Bakhtiyari ,&nbsp;Seyed Mojtaba Heydari Khoormizi ,&nbsp;Soheila pourmasumi","doi":"10.1016/j.obmed.2025.100607","DOIUrl":"10.1016/j.obmed.2025.100607","url":null,"abstract":"<div><div>Obesity is a complex medical condition characterized by excessive body fat, which poses significant health risks and affects various physiological systems. The World Health Organization (WHO) defines obesity as a Body Mass Index (BMI) of 30 or higher. In recent decades, the prevalence of obesity has surged, emerging as a global public health crisis that intersects with various health issues, including infertility, particularly in women. This essay explores the mechanisms by which obesity impacts female fertility.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100607"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive overview of polycystic ovary syndrome: Pathophysiology, clinical features, and emerging therapeutic approaches","authors":"Larsa Naji Adam,&nbsp;Lina N. Adam","doi":"10.1016/j.obmed.2025.100606","DOIUrl":"10.1016/j.obmed.2025.100606","url":null,"abstract":"<div><div>Polycystic Ovary Syndrome (PCOS) is the leading cause of anovulatory infertility, affecting 90–95 % of women seeking fertility treatment. It is characterized by hormonal imbalances, such as elevated luteinizing hormone, androgens, and insulin, along with reduced follicle-stimulating hormone (FSH). These imbalances result in clinical features like oligomenorrhea, amenorrhea, and polycystic ovaries, and often lead to complications such as infertility, metabolic disorders, and increased cardiovascular risk. Epidemiological studies show significant regional and age-related variations in the prevalence of PCOS, highlighting the need for further research into its causes and future impact. The pathophysiology of PCOS is complex, involving genetic, endocrine, environmental, and lifestyle factors. Genetic contributors include mutations in the AR, FTO, and FSHR genes, while hyperandrogenism and insulin resistance are key endocrine disruptions. Environmental and lifestyle factors, such as diet, obesity, and exposure to endocrine-disrupting chemicals, also worsen symptoms. Clinically, PCOS presents with a range of symptoms, including menstrual irregularities, hirsutism, infertility, obesity, and associated metabolic and cardiovascular risks. The condition also significantly affects mental health and quality of life. Emerging therapies, including personalized medicine and complementary approaches, offer promise for more effective, individualized treatments. This review provides an overview of PCOS, its pathophysiology, clinical manifestations, diagnostic criteria, and management options, with the aim of informing clinical practice and guiding future research.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100606"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The acute effects of animal and plant-based milk intake before endurance exercise in overweight and obese women: Interplay between lipolysis and proteolysis","authors":"Soheila Moghaddam Eftekhari ,&nbsp;Marziyeh Saghebjoo ,&nbsp;Fatemeh Islami ,&nbsp;Fereshteh Ahmadabadi","doi":"10.1016/j.obmed.2025.100603","DOIUrl":"10.1016/j.obmed.2025.100603","url":null,"abstract":"<div><h3>Aims</h3><div><em>Obesity is</em> the underlying cause of several <em>metabolic disorders, and regular endurance exercise (EE) is considered one of the main weight loss strategies. Since females have less muscle mass than males, maintaining muscle mass is crucial for them in specific exercise considerations and nutritional strategies designed to produce weight loss.</em> This study aimed to investigate the response of serum levels of glycerol, urea, insulin-like growth factor-1 (IGF-1), and cortisol to performing an EE session following the consumption of animal and plant-based milk in overweight and obese young women.</div></div><div><h3>Methods</h3><div>After 8 h of overnight fasting, 10 female participants consumed 500 ml of water, low-fat cow's milk (LFCM), and soy milk (SM), randomly in three sessions, then performed 90-min EE at 65 % VO2max. Biochemical parameters were measured immediately before and after and 1 h after each session of EE.</div></div><div><h3>Results</h3><div>The glycerol level increased immediately after EE in the LFCM and water groups compared to the baseline (P &lt; 0.001), and decreased 1 h after EE in both consumption groups compared to the immediately after EE (P values 0.002, &lt;0.001; respectively). Despite the significant increase in urea level 1 h after EE compared to the baseline level with SM consumption (P &lt; 0.001) and immediately and 1 h after EE compared to the baseline with LFCM consumption (P values 0.001, &lt;0.001; respectively), the urea levels remained unchanged with water consumption. Cortisol level was decreased immediately and 1 h after EE in all three groups compared to the baseline (P &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Drinking LFCM and water before the EE under overnight fasting conditions similarly stimulates lipolysis, as evidenced by comparable increases in glycerol level. Additionally, SM consumption appears to enhance anti-degradation pathways of muscle proteins compared to LFCM, based on lower urea levels post-exercise.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100603"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protein phosphatase 6 as an important downstream target of fibroblast growth 21 and its therapeutic analogues in attenuating MASH development","authors":"Jia Nuo Feng ,&nbsp;Qingchun Tong ,&nbsp;Tianru Jin","doi":"10.1016/j.obmed.2025.100602","DOIUrl":"10.1016/j.obmed.2025.100602","url":null,"abstract":"","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100602"},"PeriodicalIF":0.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evaluation of safety and efficacy of biozen syrup in patients with hyperlipidemia","authors":"Rajappan Chandra Satish Kumar ,&nbsp;Subramaniam Nandhini ,&nbsp;Bhuvaneshwaran Mothishwaran ,&nbsp;Chittaranjan Das ,&nbsp;Anavarathan Vallipuram ,&nbsp;Muhasaparur Ganesan Rajanandh","doi":"10.1016/j.obmed.2025.100601","DOIUrl":"10.1016/j.obmed.2025.100601","url":null,"abstract":"<div><h3>Background</h3><div>The increasing prevalence of hyperlipidemia has become one of the greatest threats to public health. While pharmacological treatments are effective for the management of hyperlipidemia, alternative approaches like dietary supplements are gaining interest for their natural benefits. The present study aimed to evaluate the safety and efficacy of biozen syrup comprised of garlic, apple-cider vinegar, lemon and honey for controlling patients with hyperlipidemia.</div></div><div><h3>Methods</h3><div>A prospective, open-label study was conducted on patients who had hyperlipidemia. Patients were given with biozen syrup (15 ml in 100 ml warm water) twice daily for 90 days. Clinical assessments and laboratory findings were compared before (day 0) and after (day 90) starting the treatment.</div></div><div><h3>Results</h3><div>A total of 60 patients were enrolled in the study. After administration of biozen syrup, serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-sensitivity C-reactive protein (hs-CRP), homocysteine, and apolipoprotein B levels significantly decreased (<em>p</em> &lt; 0.001). The mean serum apolipoprotein A1, high-density lipoprotein cholesterol (HDL-C) were raised post-treatment (<em>p</em> &lt; 0.001). Treatment with biozen syrup had no significant effects (<em>p</em> &gt; 0.001) on serum biochemical parameters related to liver, kidney functions and hematological parameters. Gastrointestinal disturbances was the most frequently occurred ADR (58 %).</div></div><div><h3>Conclusion</h3><div>The results demonstrated that the biozen was safe and efficacious in lowering the levels of bad cholesterol and raising the levels of good cholesterol.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100601"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the relationship between demographic characteristics, lifestyle factors, and obesity metrics among adults in Haiphong, Vietnam","authors":"Duc Minh Cap ,&nbsp;Kien Trung Dong ,&nbsp;Diem Thi Hong Nguyen ,&nbsp;Hong Thi Nguyen ,&nbsp;Khoa Xuan Tang ,&nbsp;Anh Hai Cao ,&nbsp;Linh Thuy Nguyen ,&nbsp;Tuyet Thi Hong Nguyen ,&nbsp;Minh Duc Pham","doi":"10.1016/j.obmed.2025.100600","DOIUrl":"10.1016/j.obmed.2025.100600","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to assess the association between demographic characteristics, lifestyle factors, and obesity metrics among adults in Haiphong, Vietnam.</div></div><div><h3>Materials and methods</h3><div>A community-based cross-sectional study involving 2100 participants was conducted using a multi-stage sampling technique. Data were collected through face-to-face interviews and anthropometric measurements. Overweight/obesity was defined using body mass index (BMI), whereas abdominal obesity was determined by waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR). The association between demographic characteristics, lifestyle factors, and obesity metrics was assessed using univariable and multivariable logistic regression.</div></div><div><h3>Results</h3><div>The prevalence of overweight/obesity was 18.4 % (male, 22 %; female, 16.2 %). The rates of abdominal obesity based on the WC, WHR, and WHtR were 19.3 %, 54.0 %, and 41.1 %, respectively. There was a significant difference in the prevalence of overweight/obesity and abdominal obesity between genders. Males had higher rates of overweight/obesity and abdominal obesity based on WHtR, whereas females showed higher rates of abdominal obesity based on WC and WHR. Male sex, age, education, occupation, and sedentary time were significantly associated with being overweight/obese. Female sex, age, education, residence, alcohol dependence, sedentary time, and physical activity were significantly associated with at least one abdominal obesity indicator.</div></div><div><h3>Conclusion</h3><div>The prevalence of overweight/obesity and abdominal obesity in adults was high. Both demographic factors and unhealthy lifestyle habits were associated with overweight/obesity and abdominal obesity. This suggests the need for intervention strategies to modify lifestyle behaviors tailored to each age group and gender.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100600"},"PeriodicalIF":0.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of 52-week liraglutide treatment on diabetes risk and glycaemic control in women with obesity and prior gestational diabetes. A randomized, double-blind, placebo-controlled study","authors":"Roosa Perämäki ,&nbsp;Meri-Maija Ollila ,&nbsp;Janne Hukkanen ,&nbsp;Marja Vääräsmäki ,&nbsp;Jukka Uotila ,&nbsp;Saara Metso ,&nbsp;Heidi Hakkarainen ,&nbsp;Reeta Rintamäki ,&nbsp;Eliisa Löyttyniemi ,&nbsp;Heidi Immonen ,&nbsp;Risto Kaaja","doi":"10.1016/j.obmed.2025.100596","DOIUrl":"10.1016/j.obmed.2025.100596","url":null,"abstract":"<div><h3>Aims</h3><div>We investigated the effect of 52-week liraglutide treatment on the incidence of type 2 diabetes (T2D) compared with placebo treatment in women with obesity and previous gestational diabetes (pGDM) requiring medical treatment. As secondary outcomes, the prevalence of prediabetes and glycaemic control were investigated.</div></div><div><h3>Methods</h3><div>Women were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks. Oral glucose tolerance test, C-peptide, insulin, HbA1c and lipids were determined at baseline, 26 weeks, and 52 weeks.</div></div><div><h3>Results</h3><div>In total, 75 women [mean age of 34.5 years, median BMI of 38.0 kg/m²] were assigned to liraglutide (n = 37) or placebo (n = 38). At 52 weeks, T2D was diagnosed in 3% (n = 1) of the liraglutide group and 8% (n = 2) of the placebo group (p = 0.58), and prediabetes in 27% (n = 9) and 58% (n = 15), respectively (p = 0.032). In intention-to-treat analysis, 52-week liraglutide treatment reduced fasting glucose [group × time interaction p = 0.0047; estimated treatment difference (ETD) at 52 weeks −0.5 mmol/L, p = 0.0020], HbA1c [p = 0.020; ETD -0.2% (−2.1 mmol/mol), p = 0.056], weight (p = 0.0087; ETD -6.2 kg, p = 0.20) and waist circumference (p = 0.022; ETD -3.9 cm, p = 0.25), and improved Matsuda index (p = 0.049; ETD 0.7, p = 0.011) compared with placebo.</div></div><div><h3>Conclusions</h3><div>Liraglutide reduces the prevalence of prediabetes and improves glycaemic control in women with obesity and pGDM. Due to few T2D cases, the effect of liraglutide on diabetes risk could not be reliably assessed.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100596"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey on the herbal combinations in traditional Vietnamese medicine formulas for obesity treatment based on literature","authors":"Duong Thi Huong Nguyen,&nbsp;Huy Khanh Tang,&nbsp;An Thi Hoai Nguyen,&nbsp;Luu Bao Le","doi":"10.1016/j.obmed.2025.100598","DOIUrl":"10.1016/j.obmed.2025.100598","url":null,"abstract":"<div><h3>Objectives</h3><div>Today, obesity is a significant public health concern. Traditional medicine, known for its minimal side effects and positive outcomes, is increasingly being utilized as an alternative intervention in clinical practice. This study seeks to examine Vietnamese literature to identify herbs that can aid in reducing obesity and to interpret the association rules among these herbs.</div></div><div><h3>Methods</h3><div>Four hundred thirty-six formulas were collected from 43 documents suited to inclusion criteria. Using Microsoft Excel 2016, we continuously interpreted the characteristics of 320 herbs extracted from 436 anti-obesity formulas. The Apriori algorithm, operated by R Studio version 4.3.3, investigated the association rules among core materials.</div></div><div><h3>Results</h3><div>Shan Zha (<em>Fructus crataegi</em>) is the most popular herb mentioned in 436 compounded medications. The predominant property and flavor were warm (33,02%) and sweet (52,7%), respectively. Eventually, we also found 18 association rules and screened out 7 potential anti-obesity herbs. Each rule consists of two or three components. Especially, the greatest prevalent associated law is a triple combination among Fu Ling (<em>Poria cocos</em>)<em>,</em> Ban Xia (<em>Rhizoma pinelliae</em>)<em>,</em> and Chen Pi (<em>Pericarpium citri reticulatae</em>).</div></div><div><h3>Conclusions</h3><div>This study documents traditional Vietnamese medicinal knowledge on herbs with anti-obesity properties. According to the traditional function, all of herbs can be divided into these classifications: Tonify Spleen-Qi, Move Qi and invigorate Blood, Resolve retention of food, Resolve Dampness and Promoting diuresis. Besides, the pharmacological functions of them are suppressing appetite, inhibition of fat absorption and elevation of fat metabolism rate.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100598"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The application of biohacking in obesity medicine: New perspectives on obesity's socioeconomic effects and disease mechanisms","authors":"Ammar Abdulrahman Jairoun","doi":"10.1016/j.obmed.2025.100586","DOIUrl":"10.1016/j.obmed.2025.100586","url":null,"abstract":"<div><div>Obesity is a complex health issue that affects every nation worldwide. It is associated with various economic and societal difficulties, substantial comorbidities, and complex disease mechanisms. Conventional approaches to treating obesity often do not result in tailored, sustainable health outcomes. However, new approaches to its treatment may be found in biohacking, an approach defined by the combined use of technology, advances in science, and self-experimentation. This Editorial explores biohacking's potential role in managing obesity, particularly in addressing its behavioral factors, socioeconomic effects, and disease mechanisms. Biohacking aims to manipulate core biological processes such as gene expression, systemic inflammation, and cellular health to reduce the risks associated with obesity and enhance metabolic health. These techniques include nutrigenomics, microbiome manipulation, and intermittent fasting with wearable technologies and ongoing glucose monitors, allowing people to access their health data in real time and personalize their approach to managing their weight. With the support of habit-establishing strategies and mindfulness tools, behavioral interventions underpinned by biohacking principles can deliver long-term changes to people's lifestyles. Biohacking offers potential benefits not only for the individual but also for society, where it may lessen healthcare inequalities by providing low-cost, accessible tools. Nonetheless, ethical concerns about self-experimentation and biohacking's equitability and safety remain. However, integrating biohacking into conventional medicine could transform obesity management and tackle its many associated factors by delivering tailored, preventative treatment options.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100586"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}